- Organizations: SightGlass Vision
Pipeline
SightGlass unveils 18-month data on DOT spectacle lenses for myopia
Latest findings follow 12-month data reported at ARVO; results show over 50% of pediatric patients had no clinically meaningful disease progression.
Pipeline
New DOT lens data finds 75% pediatric myopia management efficacy after 12 months
Latest clinical results support safety and effectiveness of SightGlass Vision’s Diffusion Optics Technology spectacle lenses—including 1-year following discontinued wear.
Products
FDA grants Breakthrough Device Designation to SightGlass Vision's DOT spectacle lenses
Technology is designed to potentially slow myopia progression in pediatric patients aged 6-13.
Products
Real-world efficacy of DOT lenses evaluated for pediatric myopia
Findings from an ECP-targeted survey identifies beliefs and behaviors of a positive environment, including major driving factors of the future.
Research
Four-year data continues to support DOT spectacle lenses for myopia
Four-year data continues to support DOT spectacle lenses for myopia
Research